There Is No Association Between Patient Outcomes and Demographics in an Open-Label Safety and Efficacy Study of RBX2660, a Microbiota-Based Drug for Recurrent Clostridium difficile Infection Article
Full Text via DOI: 10.14309/00000434-201710001-00139
Web of Science: 000439259000137
International Collaboration